Deciding whether to sell shares of Johnson & Johnson (NYSE: JNJ) depends on your individual portfolio strategy, asset allocation goals, and income requirements. As a foundational healthcare blue-chip with massive pharmaceutical and medical technology segments, JNJ is historically favored by long-term investors seeking stability and dependable dividend growth. Selling might be considered if you are rebalancing away from healthcare exposure or seeking higher-growth, risk-on assets, but many conservative portfolios retain it as a core defensive holding.